OptimizeRx Statistics
Total Valuation
OptimizeRx has a market cap or net worth of $160.13 million. The enterprise value is $179.94 million.
Important Dates
The next confirmed earnings date is Monday, May 12, 2025, after market close.
| Earnings Date | May 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
OptimizeRx has 18.49 million shares outstanding. The number of shares has increased by 6.82% in one year.
| Current Share Class | 18.49M |
| Shares Outstanding | 18.49M |
| Shares Change (YoY) | +6.82% |
| Shares Change (QoQ) | +0.52% |
| Owned by Insiders (%) | 14.63% |
| Owned by Institutions (%) | 59.04% |
| Float | 14.28M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 21.88 |
| PS Ratio | 1.72 |
| Forward PS | 1.60 |
| PB Ratio | 1.37 |
| P/TBV Ratio | 261.22 |
| P/FCF Ratio | 33.52 |
| P/OCF Ratio | 32.75 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.95 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 37.67 |
Financial Position
The company has a current ratio of 2.89, with a Debt / Equity ratio of 0.28.
| Current Ratio | 2.89 |
| Quick Ratio | 2.77 |
| Debt / Equity | 0.28 |
| Debt / EBITDA | n/a |
| Debt / FCF | 6.95 |
| Interest Coverage | -1.01 |
Financial Efficiency
Return on equity (ROE) is -16.51% and return on invested capital (ROIC) is -2.48%.
| Return on Equity (ROE) | -16.51% |
| Return on Assets (ROA) | -2.19% |
| Return on Invested Capital (ROIC) | -2.48% |
| Return on Capital Employed (ROCE) | -4.08% |
| Revenue Per Employee | $714,163 |
| Profits Per Employee | -$155,891 |
| Employee Count | 129 |
| Asset Turnover | 0.52 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, OptimizeRx has paid $725,000 in taxes.
| Income Tax | 725,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -5.57% in the last 52 weeks. The beta is 1.18, so OptimizeRx's price volatility has been higher than the market average.
| Beta (5Y) | 1.18 |
| 52-Week Price Change | -5.57% |
| 50-Day Moving Average | 7.25 |
| 200-Day Moving Average | 6.90 |
| Relative Strength Index (RSI) | 60.04 |
| Average Volume (20 Days) | 231,532 |
Short Selling Information
The latest short interest is 1.74 million, so 9.43% of the outstanding shares have been sold short.
| Short Interest | 1.74M |
| Short Previous Month | 1.66M |
| Short % of Shares Out | 9.43% |
| Short % of Float | 12.21% |
| Short Ratio (days to cover) | 5.12 |
Income Statement
In the last 12 months, OptimizeRx had revenue of $92.13 million and -$20.11 million in losses. Loss per share was -$1.10.
| Revenue | 92.13M |
| Gross Profit | 59.38M |
| Operating Income | -6.22M |
| Pretax Income | -25.32M |
| Net Income | -20.11M |
| EBITDA | -1.89M |
| EBIT | -6.22M |
| Loss Per Share | -$1.10 |
Full Income StatementBalance Sheet
The company has $13.38 million in cash and $33.19 million in debt, giving a net cash position of -$19.81 million or -$1.07 per share.
| Cash & Cash Equivalents | 13.38M |
| Total Debt | 33.19M |
| Net Cash | -19.81M |
| Net Cash Per Share | -$1.07 |
| Equity (Book Value) | 117.00M |
| Book Value Per Share | 6.34 |
| Working Capital | 35.32M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $4.89 million and capital expenditures -$112,000, giving a free cash flow of $4.78 million.
| Operating Cash Flow | 4.89M |
| Capital Expenditures | -112,000 |
| Free Cash Flow | 4.78M |
| FCF Per Share | $0.26 |
Full Cash Flow StatementMargins
Gross margin is 64.45%, with operating and profit margins of -6.75% and -21.83%.
| Gross Margin | 64.45% |
| Operating Margin | -6.75% |
| Pretax Margin | -21.04% |
| Profit Margin | -21.83% |
| EBITDA Margin | -2.05% |
| EBIT Margin | -6.75% |
| FCF Margin | 5.19% |
Dividends & Yields
OptimizeRx does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.82% |
| Shareholder Yield | n/a |
| Earnings Yield | -12.56% |
| FCF Yield | 2.98% |
Analyst Forecast
The average price target for OptimizeRx is $9.06, which is 4.74% higher than the current price. The consensus rating is "Buy".
| Price Target | $9.06 |
| Price Target Difference | 4.74% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on May 14, 2018. It was a reverse split with a ratio of 0.33333:1.
| Last Split Date | May 14, 2018 |
| Split Type | Reverse |
| Split Ratio | 0.33333:1 |
Scores
OptimizeRx has an Altman Z-Score of 1.98 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.98 |
| Piotroski F-Score | 5 |